The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Dallas VA Medical Center

Status: Completed

Conditions: Esophagitis; Reflux Esophagitis; Gastroesophageal Reflux Disease

Treatments: Other: Cessation of Acid Suppressing Medications

Study type: Interventional

Funder types: Other U.S. Federal agency; NIH

Identifiers

NCT01733810

2R01DK063621-11

R01DK063621 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.

Full description

Reflux esophagitis is thought to be caused by gastric acid that refluxes into the esophagus, causing injury. Newer data suggest that reflux of gastric juice into the esophagus stimulates HIF-2a, which increases production of inflammatory cytokines. These cytokines are thought to lead to reflux esophagitis. The investigators plan to study the relationship of HIF-2a to inflammatory cytokines in patients with known gastroesophageal reflux disease and reflux esophagitis.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• U.S Veteran
• History of Los Angeles Grade C erosive esophagitis

Exclusion criteria

• Inability to provide informed consent
• Esophageal varices
• Warfarin use
• Coagulopathy that precludes safe biopsy of the esophagus
• Comorbidity that precludes safe participation in the study
• Allergy to fluorescein sodium
• Pregnancy

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Reflux Patients

Experimental group

Description:

Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.

Treatment:

Other: Cessation of Acid Suppressing Medications